Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial

Barry Gumbiner; Brooke Esteves; Vanessa Dell; Tenshang Joh; Pamela D. Garzone; Alison Forgie; Chandrasekhar Udata

doi:10.1007/s12020-018-1597-1

Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial

Endocrine ◽

10.1007/s12020-018-1597-1 ◽

2018 ◽

Vol 62 (2) ◽

pp. 371-380 ◽

Cited By ~ 4

Author(s):

Barry Gumbiner ◽

Brooke Esteves ◽

Vanessa Dell ◽

Tenshang Joh ◽

Pamela D. Garzone ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Controlled Trial ◽

Phase 1 ◽

Double Blind ◽

Glucagon Receptor ◽

Double Blind Placebo ◽

Dose Study ◽

Glucagon Receptor Antagonist

Download Full-text

Review for "Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial (MIRAD trial)"

10.1111/dom.13809/v2/review3 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Mineralocorticoid Receptor ◽

Controlled Trial ◽

Liver Fat ◽

Double Blind ◽

Mineralocorticoid Receptor Antagonist ◽

Double Blind Placebo

Download Full-text

Author response for "Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial (MIRAD trial)"

10.1111/dom.13809/v2/response1 ◽

2019 ◽

Author(s):

Marie Louise Johansen ◽

Morten Schou ◽

Patrick Rossignol ◽

Maria Refsgaard Holm ◽

Jon Rasmussen ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Mineralocorticoid Receptor ◽

Controlled Trial ◽

Liver Fat ◽

Author Response ◽

Double Blind ◽

Mineralocorticoid Receptor Antagonist ◽

Double Blind Placebo

Download Full-text

Decision letter for "Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial (MIRAD trial)"

10.1111/dom.13809/v2/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Mineralocorticoid Receptor ◽

Controlled Trial ◽

Liver Fat ◽

Double Blind ◽

Mineralocorticoid Receptor Antagonist ◽

Double Blind Placebo

Download Full-text

Review for "Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial (MIRAD trial)"

10.1111/dom.13809/v1/review3 ◽

2019 ◽

Author(s):

Ahmed Alshawi

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Mineralocorticoid Receptor ◽

Controlled Trial ◽

Liver Fat ◽

Double Blind ◽

Mineralocorticoid Receptor Antagonist ◽

Double Blind Placebo

Download Full-text

1089-P: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of HD-6277, a Potent and Selective G-Protein-Coupled Receptor 40 (GPR40) Agonist, in Patients with Type 2 Diabetes Mellitus

Diabetes ◽

10.2337/db20-1089-p ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 1089-P

Author(s):

KI-HWAN KIM ◽

HYE-JUNG YANG ◽

MYOUNGKI BAEK

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

G Protein ◽

Phase 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Study ◽

G Protein Coupled

Download Full-text

Review for "Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial (MIRAD trial)"

10.1111/dom.13809/v1/review2 ◽

2019 ◽

Author(s):

Gabor Firneisz

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Mineralocorticoid Receptor ◽

Controlled Trial ◽

Liver Fat ◽

Double Blind ◽

Mineralocorticoid Receptor Antagonist ◽

Double Blind Placebo

Download Full-text

Review for "Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial (MIRAD trial)"

10.1111/dom.13809/v2/review4 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Mineralocorticoid Receptor ◽

Controlled Trial ◽

Liver Fat ◽

Double Blind ◽

Mineralocorticoid Receptor Antagonist ◽

Double Blind Placebo

Download Full-text

Review for "Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial (MIRAD trial)"

10.1111/dom.13809/v1/review5 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Mineralocorticoid Receptor ◽

Controlled Trial ◽

Liver Fat ◽

Double Blind ◽

Mineralocorticoid Receptor Antagonist ◽

Double Blind Placebo

Download Full-text

Review for "Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial (MIRAD trial)"

10.1111/dom.13809/v1/review4 ◽

2019 ◽

Author(s):

Emma Baldry

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Mineralocorticoid Receptor ◽

Controlled Trial ◽

Liver Fat ◽

Double Blind ◽

Mineralocorticoid Receptor Antagonist ◽

Double Blind Placebo

Download Full-text

Review for "Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial (MIRAD trial)"

10.1111/dom.13809/v1/review1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Receptor Antagonist ◽

Mineralocorticoid Receptor ◽

Controlled Trial ◽

Liver Fat ◽

Double Blind ◽

Mineralocorticoid Receptor Antagonist ◽

Double Blind Placebo

Download Full-text